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Abstract Previous papers on resorbable poly-L-lactide-
co-D,L-lactide (PLDLLA) cages in spinal fusion have failed
to report adequately on patient-centred clinical outcome
measures. Also comparison of PLDLLA cage with a tradi-
tionally applicable counterpart has not been previously
reported. This is the ﬁrst randomized prospective study that
assesses clinical outcome of PLDLLA cage compared with
a poly-ether-ether-ketone (PEEK) implant. Twenty-six
patients were randomly assigned to undergo instrumented
posterior lumbar interbody fusion (PLIF) whereby either a
PEEK cage or a PLDLLA cage was implanted. Clinical
outcome based on visual analogue scale scores for leg pain
and back pain, as well as Oswestry Disability Index (ODI)
and SF-36 questionnaires were documented and analysed.
When compared with preoperative values, all clinical
parameters have signiﬁcantly improved in the PEEK group
at 2 years after surgery with the exception of SF-36 general
health, SF-36 mental health and SF-36 role emotional
scores. No clinical parameter showed signiﬁcant improve-
ment at 2 years after surgery compared with preoperative
values in the PLDLLA patient group. Only six patients
(50%) in the PLDLLA group showed improvement in the
VAS scores for leg and back pain as well as the ODI, as
opposed to 10 patients (71%) in the PEEK group. One-third
of the patients in the PLDLLA group actually reported
worsening of their pain scores and ODI. Three cases of
mild to moderate osteolysis were seen in the PLDLLA
group. Following up on our preliminary report, these 2-year
results conﬁrm the superiority of the PEEK implant to the
resorbable PLDLLA implant in aiding spinal fusion and
alleviating symptoms following PLIF in patients with
degenerative spondylolisthesis associated with either canal
stenosis or foramen stenosis or both and emanating from a
single lumbar segment.
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Introduction
Technical evolution in posterior lumbar interbody fusion
(PLIF) devices has witnessed the application of cage
implants fabricated from various metallic and non metallic
materials with a varying range of geometric design. Cages
fabricated from poly-ether-ether-ketone (PEEK), when
impacted with autologous bone graft, have been shown to
promote spinal interbody fusion with high fusion rates and
good to excellent clinical outcome reported in the literature
[6, 11–13]. More recently a resorbable implant fabricated
from poly-L-lactide-co-D,L-lactide (PLDLLA) was intro-
duced into clinical practice as a structural support and bone
graft containment device intended to aid lumbar spinal
interbody fusion [2, 4, 10, 16]. Although early papers were
overwhelmingly promising, appraisal of the current litera-
ture shows that little subsequent clinical data on resorbable
cages have emerged and clinical application of these
implants seems to be diminishing. Whereas several authors
have reported fusion rates as high as 92–100% after PLIF
with the aid of a PLDLLA cage [2–5, 8–10], virtually none
of these studies have prospectively assessed patient-centred
clinical outcome measures in their entire study population.
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existing treatment options. The objective of this study was
to compare the clinical outcome of lumbar interbody fusion
using Telamon PEEK
TM
with that of Telamon PLDLLA
Hydrosorb
TM
(Both Medtronic Sofamor Danek, Memphis,
TN, USA) fusion devices in a prospective randomized
clinical trial, at a minimum of 2-year follow-up.
Materials and methods
Twenty-six patients with chronic back pain and irradiating
lower extremity symptoms were randomly assigned to
undergo instrumented posterior lumbar interbody fusion
whereby either a non resorbable Telamon PEEK cage or a
resorbable Telamon PLDLLA cage was implanted to aid
fusion. Randomisation was performed by means of block
stratiﬁcation over time. Stratiﬁcation of secondary patient
characteristics in the block was not performed. All patients
had degenerative spondylolisthesis and in addition either a
canal stenosis, foramen stenosis or both. Also all patients
had lower back as well as irradiating lower extremity
symptoms. The diagnosis was supported by pre-operative
radiographs (antero-posterior and lateral views as well as
ﬂexion and extension views) and MRI-scans in all patients.
The study protocol was approved by the institutional
review board and ethical committee, whilst an informed
consent was obtained from each patient. After surgery
unrestricted ambulation was permitted without any external
supportive device. Upon discharge, follow-up visits were at
3, 6, 12 and 24 months after surgery. A 10-point VAS
score, ODI and SF-36 questionnaire were obtained preop-
eratively and at each follow-up visit. A VAS score of zero
indicates no pain whilst a VAS score of 10 indicates the
worst imaginable pain. For the SF-36 questionnaires a
physical component score (PCS), mental component score
(MCS) and eight summary scores (physical functioning,
role physical, bodily pain, mental health, social function,
vitality, role emotional, and general health) were calculated
for each patient. Scores were normalized to the general
Dutch population so that a score of 50 represents the score
of the general population [1]. Fusion rate was assessed on
CT-scans at 24 months after surgery. Preoperative, intra-
operative, and follow-up examination data were entered
into a study-speciﬁc database. All statistical analyses were
performed with SPSS 15.0 for Windows. Repeated mea-
sures analyses of variance were performed on all dependent
variables to test for differences between pre-operative
values and post-operative values. In addition, correlation
between outcome variables was assessed using the Pearson
correlation (r) for continuous, and the point-biserial cor-
relation coefﬁcient (rpb) for correlation between dichoto-
mous and continuous variables. For categorical and ordinal
variables a Chi-square analysis was performed, and a
Fisher’s exact two-sided p value was computed. To test for
difference in performance between cages, the relative
post-operative scores (difference between pre- and post-
operative values) were compared using ANOVA. A p value
\0.05 was considered statistically signiﬁcant.
Results
PEEK cages were implanted in 14 patients and resorbable
PLDLLA cages were implanted in 12 patients. One patient
(PEEK cage) was lost to follow-up at 1 year after surgery
but was subsequently traced for a 2-year post surgery
assessment. Table 1 shows the baseline characteristics of
both patient groups. Considering the whole study popula-
tion, the average VAS score for back pain and leg pain,
respectively, improved from 6.1 [standard error of mean
(SEM) 0.4] prior to surgery to 4.0 (SEM 0.6, p = 0.012)
and from 5.0 (SEM 0.5) to 2.7 (SEM 0.6, p = 0.07) at
2 years after surgery. The average preoperative ODI of
20.5 (SEM 1.3) improved to 13.9 (SEM 2.2, p = 0.014) at
2 years after surgery, whilst average values for the SF-36
physical component score improved from 30.4 (SEM 1.8)
prior to surgery, to 38.8 (SEM 2.9, p = 0.004) at 2 years of
follow-up. Clinical outcome variables were interrelated.
The VAS, ODI and SF-36 PCS all showed signiﬁcant
correlations varying from r = 0.42 (VAS legs and VAS
back, p = 0.029) to r = 0.83 (SF-36 PCS and ODI,
p = 0.000). When compared with preoperative values, all
clinical parameters signiﬁcantly improved in the PEEK
Table 1 Baseline characteristics
PEEK PLDLLA p value
Mean age years (range) 44 (20–69) 53 (39–67) 0.085
Female sex no. (%) 6 (50%) 13 (92%) 0.126
Current smoker no. (%) 54 38 0.452
Radiating pain
Left leg no. 7 8 0.632
Right leg no. 10 9 0.261
Lumbar segment affected
L4–L5 2 5 0.130
L5–S1 11 7 0.130
L6–S1 1
VAS scores
For back pain 6.5 (SD 2.0) 5.6 (SD 2.2) 0.210
For leg pain 4.9 (SD 2.5) 4.5 (SD 2.5) 0.833
Oswestry Disability Index 23 (SD 6) 18 (SD 7) 0.542
SF-36 scores
PCS 27 (SD 10) 35 (SD 7) 0.029
MCS 45 (SD 11) 47 (SD 9) 0.683
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123group at 2 years after surgery compared with preoperative
values with the exception of SF-36 general health, SF-36
mental health and SF-36 role emotional scores (Table 2).
No single clinical parameter showed signiﬁcant improve-
ment at 2 years after surgery compared with preoperative
values in the PLDLLA patient group. Only six patients
(50%) in the PLDLLA group showed more than 10%
improvement in the VAS cores for leg and back pain as well
as the ODI, as opposed to 10 patients (71%) in the PEEK
group. One-third of the patients in the PLDLLA group
actually reported more than 10% worsening of their pain
scoresandODI.Figure 1showsthedegreeofdeclineinpain
scores for each treatment group at various time intervals of
follow-up. Both treatment groups demonstrate a greater
improvement at 6–12 months which is not sustained at
2 years of follow-up. Based on CT scan assessment, 13 out
of 14 patients demonstrated solid fusion in the PEEK group
(92% fusion rate) whereas 6 out of 12 patients in the PLD-
LLA group (50% fusion rate) showed solid fusion. This
difference in fusion rate is statistically signiﬁcant
p = 0.026.FusionratewassigniﬁcantlyrelatedtoVAS legs
(rpb = 0.49, p = 0.01), VAS back (rpb = 0.40, p = 0.04)
and SF-36 PCS (rpb = 0.40, p = 0.04). There was a sig-
niﬁcantly higher rate of subsidence in the PLDLLA group
compared with the PEEK group (p = 0.0414).
Three patients (all with non fusion) demonstrated signs
of osteolysis in the PLDLLA treatment group. Two patients
out of the six radiological failures (PLDLLA group)
reported in the preliminary paper have been revised. One
case with symptomatic non fusion and screw breakage in
S1 underwent an anterior interbody fusion using a PEEK
cage whilst a postero-lateral fusion was performed in a
second patient. Both patients reported worsening of their
pain scores and disability prior to revision surgery.
Discussion
Despitethesmallpatientpopulation,thisstudydemonstrates
that PLIF signiﬁcantly improves pain (VAS scores) and
disability (ODI) (Fig. 2) symptoms in patients with symp-
tomatic single segment degenerative spondylolisthesis.
PLIF with the aid of PEEK cages have been more exten-
sively studied, with clinical outcome as high as 86%
improvement based on patient-centred outcome measures
[6,11].Ourresultof71%improvementinthePEEKgroupis
in concordance with the ﬁndings in the literature. Most
published data on resorbable cages to date, however, have
focused on relatively short-term surgical outcome rather
than patient-centred outcome measures of pain, disability
and capacity for work. Coe and Vaccarro published a series
of 31 patients who underwentPLIFwith the aid of PLDLLA
implants in which only 16 patients were assessed using
SF-36 questionnaires [4]. They reported statistically sig-
niﬁcant improvement in the 12- and 24-month mean pain
scores and 24-month mean role physical scores compared
with the preoperative scores on the same scales. These
ﬁndings contrast with our current results in the PLDLLA
patient group. At a minimum of 2-year follow-up, only 50%
of the patients in the PLDLLA group demonstrated
improvementintheVASscoresforlegandbackpainaswell
as the ODI, as opposed to 71% in the PEEK patient group.
The poorer clinical outcome (based on VAS scores, ODI
and SF-36) with the PLDLLA implant is consistent with
the poorer fusion rate reported in the PLDLLA patient
group, and casts some serious doubts on the efﬁcacy of
PLDLLA cage in relieving symptoms and enhancing
posterior lumbar spinal interbody fusion. We belive that
the low fusion rate observed with PLDLLA cages is a
result of early mechanical failure leading to loss of
structural support prior to the establishment of a fusion
mass. Preclinical in vivo studies have demonstrated this
fact, with loss of mechanical integrity of PLDLLA cage
implants as early as 3 months after implantation, a feature
not observed in a PLLA cage another resorbable coun-
terpart [14, 15]. This preclinical ﬁnding suggests that the
composition of the two PLA isomers in the PLDLLA cage
may confer inherent time-dependent mechanical weakness
as compared with the mono isomer PLLA cage. Perhaps
an even more important factor that could have lead to
Table 2 Preoperative and 2-
year follow-up clinical data in
both treatment groups
SEM standard error of mean
PCS physical component score
MCS mental component score
PEEK n = 14 p value PLDLLA n = 12 p value
Preoperative
(SEM)
Postoperative
(SEM) 2 years
Preoperative
(SEM)
Postoperative
(SEM) 2 years
VAS leg pain 4.9 (0.7) 2.3 (0.7) 0.008 4.5 (0.7) 3.3 (8.7) 0.311
VAS back pain 6.5 (0.5) 4.1 (0.7) 0.028 5.6 (0.6) 3.9 (7.4) 0.117
ODI 23 (2) 14 (3) 0.015 18.1 (2.1) 14.0 (3.9) 0.300
SF-36 PCS 26.8 (2.6) 41.5 (3.0) 0.005 34.7 (2.1) 37.5 (4.7) 0.368
SF-36 MCS 45.0 (2.9) 49.0 (2.4) 0.237 46.7 (2.6) 46.5 (3.0) 0.953
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123early mechanical failure and non fusion in the PLDLLA
cage is the method of sterilization. All PLDLLA cages
used in this study were sterilized by E-beam irradiation.
Preclinical in vitro studies have demonstrated the adverse
effects of irradiation sterilization techniques on the time-
dependent mechanical properties of PLA-based polymers
[14]. Ethylene oxide sterilization technique has been
shown to be less detrimental in this respect. Therefore,
E-beam irradiation may have contributed to a preliminary
breakdown of the cage and consequently the higher rate of
non union in our study (Fig. 3).
Worsening of symptoms seen in 33% of the patients in
the PLDLLA group remain worrisome, and may be a result
of the lower fusion rate proffered by the resorbable cage.
This is supported by signiﬁcant correlations between poor
fusion rates on the one hand and worsening of pain scores
on the other hand. The occurrence of osteolysis and a
relatively high rate of subsidence associated with the
PLDLLA cage may also be important contributing factors
in the poorer clinical outcome as observed in this patient
group. The higher rate of subsidence is most likely related
to early mechanical failure which in itself can be an
important contributory factor in the occurrence of osteol-
ysis. It is, however, important to note that a potential
underlying low-grade infection has not been ruled out in
these cases of osteolysis. In both treatment groups, initial
improvement at 6–12 months after surgery is apparently
not sustained at 2 years of follow-up. This ﬁnding is con-
sistent with other reports in the literature [7]. We have
found no underlying reason for worsening of symptoms at
2 years in our study population.
Following up on our preliminary report, the 2-year
results conﬁrm the superiority of the PEEK implant to the
resorbable PLDLLA implant in aiding spinal fusion and
alleviating symptoms following PLIF in patients with
degenerative spondylolisthesis associated with either canal
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123stenosis or foramen stenosis or both and emanating from a
single lumbar segment.
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